Skip to main content
SpringerLink
Log in

Influence of Expedited Programs in the United States on Oncology Drug Development in Japan

  • Global Perspectives: Original Article
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

Background

Recent trends in globalization and the complexity of drug development have resulted in the possibility that expedited programs in one country may now influence drug development in another. We examined the effects of expedited programs in the United States on the development of oncology drugs in Japan.

Methods

Among oncology drugs approved in Japan between 2007 and 2016, we analyzed those that were approved in both the United States and Japan. The development period was calculated by subtracting the start date of the first clinical study or the investigational new drug application date from the drug approval date in the respective country. All data were obtained from publicly disclosed information.

Results

We analyzed a total of 108 approvals for oncology drugs. The difference in the development start date between the United States and Japan for drugs granted Breakthrough Therapy designation was smaller than that for drugs without this designation (P <.01). The development period in Japan for drugs granted Breakthrough Therapy, Accelerated Approval or Fast Track designations was significantly shorter than that for drugs without these designations (P <.05). In addition, the development period of oncology drugs in Japan tended to be significantly shorter as the number of expedited program designations increased (P <.006 for trend).

Conclusions

The characteristics and the target disease of the drug that could be eligible for expedited program(s) in the United States, which was supported by the designation, were one of the factors influencing the development of oncology drugs in Japan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adams CP, Brantner VV. Spending on new drug development. Health Econ. 2010;19:130–141.

    Article  Google Scholar 

  2. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959–68.

    Article  CAS  Google Scholar 

  3. Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther. 2010;87:356–61.

    Article  CAS  Google Scholar 

  4. Glickman SW, McHutchison JG, Peterson ED, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360:816–823.

    Article  CAS  Google Scholar 

  5. Evers P, Greene L, Ricciardi M. The importance of early access to medicines for patients suffering from rare diseases. Regulatory Rapporteur. 2016;13(2):5–8.

    Google Scholar 

  6. Leyens L, Richer E, Melien O, Ballensiefen W, Brand A. Available tools to facilitate early patient access to medicines in the EU and the USA: analysis of conditional approvals and the implications for personalized medicine. Public Health Genomics. 2015;18(5):249–59.

    Article  Google Scholar 

  7. Kepplinger EE. FDA’s expedited approval mechanisms for new drug products. Biotechnol Law Rep. 2015;34(1):15–37.

    Article  Google Scholar 

  8. Guidance for industry: expedited programs for serious conditions––drugs and biologics. https://www.fda.gov/downloads/Drugs/Guidances/UCM358301.pdf. Accessed August 6, 2017.

  9. Designating an orphan product: drugs and biological products. FDA website. https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm. Accessed August 6, 2017.

  10. Pariser AR, Robb M, Sherman RE. Expedited programs for drug development and approval. Opin Orphan Drugs. 2013;1(7):507–510.

    Article  Google Scholar 

  11. World Health Organization. Cancer. WHO website.http://www.who.int/cancer/en/ Accessed August 6, 2017.

  12. Ministry of Health, Labour and Welfare, Demographic Statistics Report [in Japanese]. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai15/dl/gaikyou27.pdf Accessed August 6, 2017.

  13. Buffery D. Innovation tops current trends in the 2016 oncology drug pipeline. Am Health Drug Benefits. 2016;9(4):233–238.

    PubMed  PubMed Central  Google Scholar 

  14. Maeda H, Kurokawa T. Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States. J Clin Pharmacol. 2015;55(5):481–489.

    Article  Google Scholar 

  15. Milne CP. Prospects for rapid advances in the development of new medicines for special medical needs. Clin Pharmacol Ther. 2014;95(1):98–109.

    Article  Google Scholar 

  16. Shirotani M, Suwa T, Kurokawa T, Chiba K. Efficient clinical trials in Japan: bridging studies versus participation in global clinical trials. J Clin Pharmacol. 2014;54:438–445.

    Article  Google Scholar 

  17. Uyama Y, Shibata T, Nagai N, et al. Successful bridging strategy based on ICH E5 guideline for drugs approved in Japan. Clin Pharmacol Ther. 2005;78:102–113.

    Article  Google Scholar 

  18. Molzon JA, Giaquinto A, Lindstrom L, et al. The value and benefits of the International Conference on Harmonization to drug regulatory authorities: advancing harmonization for better public health. Clin Pharmacol Ther. 2011;89(4):503–511.

    Article  CAS  Google Scholar 

  19. Asano K, Tanaka A, Sato H, Uyama Y. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective. Clin Pharmacol Ther. 2013;94(2):195–198.

    Article  CAS  Google Scholar 

  20. Ministry of Health, Labour and Welfare. Basic principles on global clinical trials. 2007. http://www.pmda.go.jp/files/000153265.pdf. Accessed at August 6, 2017.

  21. Hartmann M, Christine MN, Pfaff O. Approval probabilities and regulatory review patterns for anticancer drugs in the European union. Crit Rev Oncol Hematol. 2013;87:112–121.

    Article  Google Scholar 

  22. Bender, Ralf, Stefan Lange. Adjusting for multiple testing—when and how? J Clin Epidemiol. 2001;54(4):343–349.

    Article  CAS  Google Scholar 

  23. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.

    Article  CAS  Google Scholar 

  24. Kesselheim AS, Wang B, Franklin JM, Darrow JJ. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ. 2015;351–357.

  25. Shea M, Ostermann L, Hohman R, et al. Impact of breakthrough therapy designation on cancer drug development. Nat Rev Drug Discov. 2016;15(3):152.

    Article  CAS  Google Scholar 

  26. Japan Ministry of Health, Labour and Welfare. Sakigake designation of medical devices and regenerative medicine products [in Japanese]. http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000094368.html. Accessed August 6, 2017.

  27. Kondo H, Hata T, Ito K, Koike H, Kono N. The current status of Sakigake designation in Japan, PRIME in the European Union, and Breakthrough Therapy designation in the United States. Therapeutic Innovation & Regulatory Science. 2017;51(1):51–54.

    Article  Google Scholar 

  28. Hara A, Sato D, Sahara Y. New governmental regulatory system for stem cell—based therapies in Japan. Therapeutic Innovation & Regulatory Science. 2014;48(6):681–688.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Global Regulatory Science, Gifu Pharmaceutical University, Gifu, Japan

    Makoto Tanaka MS, Naoki Matsumaru PhD & Katsura Tsukamoto PhD

  2. Development Project Management, Astellas Pharma Inc, 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan

    Makoto Tanaka MS

Authors
  1. Makoto Tanaka MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoki Matsumaru PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katsura Tsukamoto PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makoto Tanaka MS.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanaka, M., Matsumaru, N. & Tsukamoto, K. Influence of Expedited Programs in the United States on Oncology Drug Development in Japan. Ther Innov Regul Sci 53, 199–206 (2019). https://doi.org/10.1177/2168479018769288

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479018769288

Keywords

Search

Navigation